Clinical Trial Update: Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating naltrexone for individuals with hazardous drinking in a smoking-cessation program; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder
• Tobacco Use Disorder

Drugs mentioned

• Naltrexone (Naltrexone)

Snippet

Sponsor: Brown University | Conditions: Hazardous Drinking, Cigarette Smoking | Phase 2 | Status: COMPLETED | Results posted: 2017-05-15